Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 58

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Psoriatic arthropathy

Not yet recruiting

A Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Azienda Sanitaria Universitaria Friuli Centrale

Anal fistula+1

Not yet recruiting

Comparing Gadopiclenol and Gadobutrol MRI Scans for Detecting Perianal Fistulas in Patients with Crohn's Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Toxic epidermal necrolysis

Not yet recruiting

Study of Tildrakizumab for Eye Problems in Patients with Lyell Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:TOXILYON

Vitiligo

Not yet recruiting

A study testing pioglitazone for adults with non-segmental vitiligo to see if it works and is safe when used with light therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Pioglitazone
  • Sponsor:I.F.O. Istituti Fisioterapici Ospitalieri

Multiple sclerosis+1

Not yet recruiting

A study testing hydroxychloroquine to reduce brain inflammation in patients with progressive multiple sclerosis

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxychloroquine Sulfate
  • Sponsor:Varsinais-Suomen hyvinvointialue

Systemic lupus erythematosus+1

Not yet recruiting

A Study of Obecabtagene Autoleucel for Patients with Severe Lupus and Active Kidney Inflammation Not Responding to Standard Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Autolus Limited

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not yet recruiting

Testing avacopan added to standard treatment in patients with ANCA-associated vasculitis with severe kidney damage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma

Not yet recruiting

A Study Testing Anti-CD19 CAR T-Cell Therapy in Patients with Systemic Sclerosis Who Did Not Respond to Immunosuppressive Drugs

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Multiple sclerosis+1

Not yet recruiting

Testing Antibiotic Treatment Strategies for Patients with Bladder Bacteria Without Symptoms Receiving Botulinum Toxin A Bladder Injections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Lille

Conjunctivitis allergic+1

Not yet recruiting

A Study Comparing Tacrolimus and Ciclosporin Eye Drops for Children and Adults with Moderate to Severe Vernal Keratoconjunctivitis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Ciclosporin
  • Sponsor:Laboratoires Thea

Conjunctivitis allergic

Not yet recruiting

Testing Intralymphatic Allergen Immunotherapy for Teenagers and Adults with Grass Pollen Allergy Causing Hay Fever or Asthma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:University Of Foggia

Endocrine ophthalmopathy

Not yet recruiting

Study Using Gallium-68 FAPI PET/MRI Imaging to Measure Disease Activity in Patients with Graves' Eye Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.